A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

ID#: NCT05130437

Age: 1 year - 66+

Gender: All

Healthy Subjects: No

Study Phase: Phase 1/Phase 2

Recruitment Status: Recruiting

Start Date: November 09, 2021

End Date: December 04, 2031

Contact Information:
Moderna WeCare Team
1-866-663-3762
Summary: The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).
Eligibility:

Inclusion Criteria:

- Participated in Study mRNA-3927-P101.

- Completed the EOT Visit in Study mRNA-3927-P101 within 10 days of first dose of mRNA-3927 in current study.

Exclusion Criteria:

- Not expected to receive clinical benefit from continued mRNA-3927 administration, in the opinion of the Investigator.

- Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the individual at increased risk by participating in this study.

- History of liver and/or kidney transplant.
Find a Clinical Trial Find Cancer Clinical Trials